Atorvastatin reduced soluble receptors of TNF-alpha in systemic lupus erythematosus

Clinical and Experimental Rheumatology

Volumn 34, Issue 1, 2016, Pages 42-48

  Ferreira, Gilda Aparecida ^a   Teixeira, Antonio Lúcio ^a   Calderaro, Debora Cerqueira ^a   Sato, Emília Inoue ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Atherosclerosis; Atorvastatin; Receptors; Systemic lupus erythematosus; Tumour necrosis factor

Indexed keywords

ATORVASTATIN; DNA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 1; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 2; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TNFRSF1A PROTEIN, HUMAN; TNFRSF1B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ABDOMINAL OBESITY; ADULT; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MUSCULOSKELETAL DISEASE ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SCORING SYSTEM; SLEDAI; SLICC SCORE; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; BRAZIL; CONTROLLED CLINICAL TRIAL; DOWN REGULATION; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; ATORVASTATIN CALCIUM; BIOMARKERS; BRAZIL; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84958757805     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. WADE SN, MAJOR AS: The problem of accelerated atherosclerosis in systemic lupus erythematosus: Insights into a complex comorbidity. Thromb Haemost 2011; 106: 849-57.
2. SCHUR PH, GLADMAN DD: Overview of the clinical manifestations of systemic lupus erythematosus in adults. In UpToDate online. Accessed on 03/05/12.
3. ZHU LJ, LANDOLT-MARTICORENA C, LI T et al.: Altered expression of TNF-α signaling pathway proteins in systemic lupus erythematosus. J Rheumatol 2010; 37: 1658-66.
4. ZHU LJ, YANG X, YU XQ: Anti-TNF-α in systemic lupus erythematosus. J Biomed Biotechnol 2010; 2010: 465898.
5. PARAMESWARAN N, PATIAL S: Tumor necrosis factor-α signaling in macrophages. Crit Ver Eukaryot Gene Expr 2010; 20: 87-103.
6. COSTENBADER KH, SHUR PH: Coronary heart disease in systemic lupus erythematosus. In UpTo date online. Accessed on 03/04/12.
7. MANZI S, MEILAHN EM, RAIRIE JE et al.:Age-specific incidence rates of myocardial infarction and angina in women with sustemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408-15.
8. HAK AE, KARLSON EW, FESKANICH D et al.:Systemic lupus erythematosus and the risk of cardiovascular disease: results form the nurses'health study. Artrhitis Rheum 2009; 61: 1396.
9. ESDAILE JM, ABRAHAMOWICZ M, GRODZICKY T et al.: Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331-37.
10. CHIN CW, TAN RS, THUMBOO J: Endothelial function and arterial stiffness assessment as early surrogate markers of vascular risk in patients with systemic lupus erythematosus. Clin Exp Rheumatol 2013; 31: 295-301.
11. KAHLENBERG JM, KAPLAN MJ: The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus. Arthritis Res Ther 2011; 13: 203-10.
12. SABRY A, SHEASHAA H, EL-HUSSEINI A et al.: Proinflammatory cytokines (TNF-α and IL-6) in Egyptian patients with SLE: its correlation with disease activity. Cytokine 2006; 35: 148-53.
13. WECKERLE CE, MANGALE D, FRANEK BS et al.: Large-scale analysis of tumor necrosis fator-α levels in Systemic Lupus Erythematosus. Arthritis Rheum 2011; 64: 2947-52.
14. MASON JC: Statins and their role in vascular protection. Clin Sci 2003; 105: 251-66.
15. ASCER E, BERTOLAMI MC, VENTURNELLI ML et al.: Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 2004; 177: 161-6.
16. MERONI PL, LUZZANA, VENTURA D: Antiinflammatory and immunomodulating properties of statins. An additional tool for the therapeutic approach of systemic autoimmune disease? Clin Rev Allerg Immunol 2002; 23:263-77.
17. FERREIRA GA, NAVARRO TP, TELLES RW et al.: Atorvastatin therapy improves endothelial- dependent vasodilation in patients with systemic lupus erythematosus: a 8 weeks controlled Trial. Rheumatology (Oxford) 2007; 46: 1560-65.
18. FERREIRA GA, TEIXEIRA AL, SATO EI: Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus. Lupus 2010; 19: 927-34.
19. HOCHBERG MG: Update the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
20. BOMBARDIER C, GLADMAN DD, UROWITZ MB, CARON D, CHANG CH: Derivation of the SLEDAI: a disease activity index for lupus patients: The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-40.
21. GLADMAN DD, UROWITZ MB, GOLDSMITH CH et al.: The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 809-13.
22. SCHOTTE H, WILLEKE P, TIDOW N et al.: Extended haplotype analysis reveals an association of TNF polymorphisms with susceptibility to systemic lupus erythematosus beyond HLA-DR3. Scand J Rheumatol 2005; 34: 114-21.
23. JIMÉNEZ-MORALES S, VELÁZQUEZ-CRUZ R, RAMÍREZ-BELLO J et al.: Tumor necrosis factor-alpha is a common genetic risk factor for asthma, juvenile rheumatoid arthritis, and systemic lupus erythematosus in a Mexican pediatric population. Hum Immunol 2009; 70:251-6.
24. McHUGH NJ, OWEN P, COX B et al.: MHC class II, tumor necrosis factor alpha, and lymphotoxin alpha gene haplotype associations with serological subsets of systemic lupus erythematosus. Ann Rheum Dis 2006; 65: 488-94.
25. POSTAL M, APPENZELLER S: The role of tumor necrosis factor-alpha (TNF-α) in the pathogenesis of systemic lupus erythematosus. Cytokine 2011; 56: 537-43.
26. ARINGER M, SMOLEN JS: Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. Arthritis Res Ther 2003; 5: 172-7.
27. ARINGER M, ZIMMERMANN C, GRANINGER WB et al.: TNF-α is an essential mediator in lupus nephritis. Arthritis Rheum 2002; 46:3418-9.
28. SVENUNGSSON E, GUNNARSSON I, FEI G et al.: Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 2003; 48: 2533-40.
29. YAP DY, LAI KN: Cytokines and their roles in the pathogenesis of systemic lupus erythematosus:from basics to recent advances. J Biomed Biotechnol 2010; 2010: 365083.
30. GABAY C, CAKIR N, MORAL F et al.: Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997; 24: 303-8.
31. ALESSANDRI AL, SOUZA AL, OLIVEIRA SC et al.: Concentrations of CXCL8, CXCL9 and sTNFR1 in plasma of patients with pulmonary tuberculosis undergoing treatment. Inflamm Res 2006; 55: 528-33.
32. MOURA AS, CARMO RA, TEIXEIRA AL et al.: Soluble inflammatory markers as predictors of liver histological changes in patients with chronic hepatitis C virus infection. Eur J Clin Microbiol Infect Dis 2010; 29: 1153-61.
33. ARINGER M, SMOLEN JS: Tumor necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus 2004; 13:344-7.
34. ARINGER M, SMOLEN JS: Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. Expert Opin Drug Saf 2008; 7: 411-9.
35. ARINGER M, FEIERL E, STEINER G et al.:Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death. Lupus 2002; 11: 102-8.
36. HOTAMISLIGIL GS, SHARGILL NS, SPIEGELMAN BM et al.: Adipose expression of tumor necrosis factor-alpha: direct role in obesitylinked insulin resistance. Science 1993; 259:87-91.
37. GREEN A, DOBIAS SB, WALTERS DJ et al.: Tumor necrosis factor increases the rate of lipolysis in primary cultures of adipocytes without altering levels of hormone-sensitive lipase. Endocrinology 1994; 134: 2581-88.
38. ORMSETH MJ, SWIFT LL, FAZIO S et al.: Free fatty acids are associated with metabolic syndrome and insulin resistance, but not inflammation in SLE patients. Lupus 2013; 22:26-33.
39. ILOWITE NT, SAMUEL P, GINZLER E, JACOBSON MS: Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 1988; 31: 859-63.
40. BORBA EF, BONFA E: Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997; 6: 533-9.
41. FROSTEGARD J, ULFGREN AK, NYBERG P et al.: Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophagestimulating cytokines. Atherosclerosis 1999; 145: 33-43.
42. SVENUNGSSON E, FEI G-Z, JENSEN-URSTAD K et al.: TNF-alpha: a link between hypertriglyceridemia and inflammation in SLE patients with cardiovascular disease. Lupus 2003; 12: 451-61.
43. TU H, LI Q, XIANG S et al.: Dual effects of statins therapy in systemic lupus erythematosus and SLE-related atherosclerosis: the potential role for regulatory T cells. Atherosclerosis 2012; 222: 29-33.
44. LAWMAN S, MAURI C, JURY EC et al.: Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol 2004; 173: 7641-6.
45. WU K, TIAN S, ZHOU H, WU Y: Statins protect human endothelial cells from TNF-induced via ERK5 activation. Biochem Pharmacol 2013; 85: 1753-60.